Deepika .
- Biotech Researcher, Department of Biotechnology, BMS college of Engineering, Visvesvaraya Technological University, Bengaluru, Karnataka, India
Abstract
Objective: There has been a great deal of interest in how inflammatory dermatosis and The cell interact, but the etiopathogenesis of chronic spontaneous urticaria (CSU) is still inadequately comprehended. Through bioinformatics techniques, the purpose of this work is to elucdate the molecular mechanism underlying Th-related genes in CSU and seeks to find the highest affinity drug.
Methods: The CSU RNA expression profiling dataset provided the basis for the investigation. The analysis included differentially expressed Th cell-related genes (DEThRGs), gene ontology (GO), kyoto encyclopedia of genes and genomes (KEGG), and Disease Ontology (DO). Using protein-protein interaction analysis, the hub genes were investigated. Additionally, Molecular Docking was methodically carried out with PyRx and BIOVIA discovery studio to ascertain the binding affinities between drugs and proteins.
Results: We recognised 23 DEThRGs, revealed that their primary areas of enrichment were immunomodulation and inflammatory response. Additionally, there are 8 hub genes and (BRD7 and CCAR1) were up regulated genes, while (HOXA6, CTBP2, HOXA3, HOXA5, CTBP1 and NCOR1) were down regulated genes. Furthermore, the drug–gene interaction network encompassed fifteen possible therapeutic agents that target proteins; molecular docking revealed that Azacitidine or Ivosidenib has highest binding affinity with all the 8 proteins.
Conclusion: These compounds may have a significant impact on CSU development and may even serve as biomarkers for the CSU. Additional research on the medication is possible for clinical trials and therapeutic applications. The identification of eight pivotal genes associated with CSU presents fresh perspectives, potentially serving as pivotal indicators for diagnosis and novel therapeutic approaches.
Keywords: Immunology, Chronic Spontaneous Urticaria (CSU), Th-related genes, Hub genes, Bioinformatics, Biomarker, GEO, differentially expressed genes, Inflammation.
[This article belongs to International Journal of Genetic Modifications and Recombinations(ijgmr)]
Browse Figures
References
1 Leung, D. Y. (2020). Allergic skin diseases beyond TH2. Annals of Allergy, Asthma & Immunology, 124(1), 1.
2 Stepaniuk, P., Kan, M., & Kanani, A. (2020). Natural history, prognostic factors and patient perceived response to treatment in chronic spontaneous urticaria. Allergy, Asthma & Clinical Immunology, 16(1), 1-11.
3 Prosty C, Gabrielli S, Ben-Shoshan M, Le M, Giménez-Arnau AM, Litvinov IV, Lefrançois P, Netchiporouk E. In silico identification of immune cell-types and pathways involved in chronic spontaneous urticaria. Frontiers in medicine. 2022 Jul 7;9:926753.
4 Kolkhir, P., Giménez-Arnau, A. M., Kulthanan, K., Peter, J., Metz, M., & Maurer, M. (2022). Urticaria. Nature Reviews Disease Primers, 8(1), 61.
5 Zuberbier, T., Abdul Latiff, A. H., Abuzakouk, M., Aquilina, S., Asero, R., Baker, D., … & Maurer, M. (2022). The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy, 77(3), 734-766.
6 Bumbăcea, R. S., Deaconu, C. G., & Berghea, E. C. (2019). Management problems in severe chronic inducible urticaria: Two case reports. Experimental and Therapeutic Medicine, 18(2), 960-963.
7 Giménez-Arnau, A. M., de Montjoye, L., Asero, R., Cugno, M., Kulthanan, K., Yanase, Y., … & Kaplan, A. P. (2021). The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells. The Journal of Allergy and Clinical Immunology: In Practice, 9(6), 2195-2208.
8 Saini, S. S. (2023). Urticaria and basophils. Allergology International.
9 Lecce, M., Molfetta, R., Milito, N. D., Santoni, A., & Paolini, R. (2020). FcεRI signaling in the modulation of allergic response: role of mast cell-derived exosomes. International Journal of Molecular Sciences, 21(15), 5464.
10 Maurer, M., Eyerich, K., Eyerich, S., Ferrer, M., Gutermuth, J., Hartmann, K., … & Metz, M. (2020). Urticaria: collegium internationale allergologicum (CIA) update 2020. International archives of allergy and immunology, 181(5), 321-333.
11 He, L., Yi, W., Huang, X., Long, H., & Lu, Q. (2021). Chronic urticaria: advances in understanding of the disease and clinical management. Clinical reviews in allergy & immunology, 1-25.
12 Russo, I., Cazzolla, S., Pampaloni, F., & Alaibac, M. (2022). Omalizumab for the treatment of chronic spontaneous urticaria: association between body mass index and outcome. Dermatology Practical & Conceptual, 12(4).
13 Kocaturk, E., Saini, S. S., Rubeiz, C. J., & Bernstein, J. A. (2022). Existing and investigational medications for refractory chronic spontaneous urticaria: safety, adverse effects, and monitoring. The Journal of Allergy and Clinical Immunology: In Practice.
14 Zuberbier, T., Altrichter, S., Bauer, S., Brehler, R., Brockow, K., Dressler, C., … & Maurer, M. (2023). S3 Guideline Urticaria. Part 2: Treatment of urticaria–German‐language adaptation of the international S3 guideline. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 21(2), 202-215.
15 Kolkhir, P., Grakhova, M., Bonnekoh, H., Krause, K., & Maurer, M. (2019). Treatment of urticarial vasculitis: a systematic review. Journal of Allergy and Clinical Immunology, 143(2), 458-466.
16 Hapa, F. A., & Yıldırım, F. E. (2023). Efficacy and Safety of Omalizumab Updosing in Chronic Urticaria: A Retrospective Study. Skinmed, 21(3), 170-175.
17 Tamer, F., Gulru Erdogan, F., Dincer Rota, D., Yildirim, D., & Akpinar Kara, Y. (2019). Efficacy of omalizumab in patients with chronic spontaneous urticaria and its association with serum IgE levels and eosinophil count. Acta Dermatovenerologica Croatica, 27(2), 101-101.
18 Kaplan, A. P. (2019). Treatment of urticaria: a clinical and mechanistic approach. Current Opinion in Allergy and Clinical Immunology, 19(4), 387-392.
19 Kolkhir, P., Altrichter, S., Munoz, M., Hawro, T., & Maurer, M. (2020). New treatments for chronic urticaria. Annals of Allergy, Asthma & Immunology, 124(1), 2-12.
20 Holm, J. G., & Thomsen, S. F. (2019). Omalizumab for atopic dermatitis: evidence for and against its use. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia, 154(4), 480-487.
21 Johal, K. J., & Saini, S. S. (2020). Current and emerging treatments for chronic spontaneous urticaria. Annals of Allergy, Asthma & Immunology, 125(4), 380-387.
22 Metz, M., Vadasz, Z., Kocatürk, E., & Giménez-Arnau, A. M. (2020). Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence. Clinical reviews in allergy & immunology, 59(1), 38-45.
23 Metz, M., Torene, R., Kaiser, S., Beste, M. T., Staubach, P., Bauer, A., … & Maurer, M. (2019). Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: a randomized, double‐blind, placebo‐controlled study. Allergy, 74(1), 141-151.
24 Humbert, M., Bousquet, J., Bachert, C., Palomares, O., Pfister, P., Kottakis, I., … & Papadopoulos, N. G. (2019). IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy. The Journal of Allergy and Clinical Immunology: In Practice, 7(5), 1418-1429.
25 Ludwig, C. M., Krase, J. M., & Shi, V. Y. (2021). T helper 2 inhibitors in allergic contact dermatitis. Dermatitis, 32(1), 15-18.
26 Shimoda, A., Miura, R., Tateno, H., Seo, N., Shiku, H., Sawada, S. I., … & Akiyoshi, K. (2022). Assessment of surface glycan diversity on extracellular vesicles by lectin microarray and glycoengineering strategies for drug delivery applications. Small Methods, 6(2), 2100785.
27 Abbott, T. R., Dhamdhere, G., Liu, Y., Lin, X., Goudy, L., Zeng, L., … & Qi, L. S. (2020). Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell, 181(4), 865-876.
28 Su, W., Zhao, Y., Wei, Y., Zhang, X., Ji, J., & Yang, S. Exploring the Pathogenesis of Psoriasis Complicated With Atherosclerosis via Microarray Data Analysis. Front Immunol. 2021; 12: 667690.
29 Peng, C., Zhang, Y., Lang, X., & Zhang, Y. (2023). Role of mitochondrial metabolic disorder and immune infiltration in diabetic cardiomyopathy: new insights from bioinformatics analysis. Journal of Translational Medicine, 21(1), 1-18.
30 Shao, Y., Jia, H., Huang, L., Li, S., Wang, C., Aikemu, B., … & Zheng, M. (2021). An original ferroptosis-related gene signature effectively predicts the prognosis and clinical status for colorectal cancer patients. Frontiers in oncology, 11, 711776.
31 Zhang, L., Han, L., Wang, X., Wei, Y., Zheng, J., Zhao, L., & Tong, X. (2021). Exploring the mechanisms underlying the therapeutic effect of Salvia miltiorrhiza in diabetic nephropathy using network pharmacology and molecular docking. Bioscience reports, 41(6), BSR20203520.
32 Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., … & Chanda, S. K. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature communications, 10(1), 1523.
33. Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z., & Zhang, B. (2019). WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic acids research, 47(W1), W199-W205.
34 Szklarczyk, D., Gable, A. L., Nastou, K. C., Lyon, D., Kirsch, R., Pyysalo, S., … & von Mering, C. (2021). The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic acids research, 49(D1), D605-D612.
35 Doncheva, N. T., Morris, J. H., Gorodkin, J., & Jensen, L. J. (2018). Cytoscape StringApp: network analysis and visualization of proteomics data. Journal of proteome research, 18(2), 623-632.
36 Liu, J., Zhou, S., Li, S., Jiang, Y., Wan, Y., Ma, X., & Cheng, W. (2019). Eleven genes associated with progression and prognosis of endometrial cancer (EC) identified by comprehensive bioinformatics analysis. Cancer Cell International, 19(1), 1-17.
37 Sun, Y., Cai, D., Hu, W., & Fang, T. (2022). Identifying hub genes and miRNAs in Crohn’s disease by bioinformatics analysis. Frontiers in Genetics, 13, 950136.
38 Masoudi-Sobhanzadeh, Y., Omidi, Y., Amanlou, M., & Masoudi-Nejad, A. (2019). DrugR+: a comprehensive relational database for drug repurposing, combination therapy, and replacement therapy. Computers in biology and medicine, 109, 254-262.
39 Wang, Y., Wang, Q., Huang, H., Huang, W., Chen, Y., McGarvey, P. B., … & UniProt Consortium. (2021). A crowdsourcing open platform for literature curation in UniProt. PLoS biology, 19(12), e3001464.
40 Soudani, W., Hadjadj-Aoul, F. Z., Bouachrine, M., & Zaki, H. (2021). Molecular docking of potential cytotoxic alkylating Carmustine derivatives 2-chloroethylnitrososulfamides analogues of 2-chloroethylnitrosoureas. Journal of Biomolecular Structure and Dynamics, 39(12), 4256-4269.
41 Sonar, P., Shaikh, K., Ballav, S., Basu, S., & Harer, S. (2022). Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors. Bioinformation, 18(10), 974-981.
42 Gonçalo, M., Gimenéz‐Arnau, A., Al‐Ahmad, M., Ben‐Shoshan, M., Bernstein, J. A., Ensina, L. F., … & Maurer, M. (2021). The global burden of chronic urticaria for the patient and society. British Journal of Dermatology, 184(2), 226-236.
43 Khan, S., Chopra, C., Mitchell, A., Nakonechna, A., Yong, P., & Karim, M. Y. (2022). Resistant Chronic Spontaneous Urticaria–A Case Series Narrative Review of Treatment Options. Allergy & Rhinology, 13, 21526575221144951.
44 Maurer, M., Zuberbier, T., & Metz, M. (2021). The classification, pathogenesis, diagnostic workup, and management of urticaria: an update. In Allergic Diseases–From Basic Mechanisms to Comprehensive Management and Prevention (pp. 117-133). Cham: Springer International Publishing.
45 Kulthanan, K., Church, M. K., Grekowitz, E. M., Hawro, T., Kiefer, L. A., Munprom, K., … & Maurer, M. (2022). Evidence for histamine release in chronic inducible urticaria–A systematic review. Frontiers in Immunology, 13, 901851.
46 Hu, X., Ni, S., Zhao, K., Qian, J., & Duan, Y. (2022). Bioinformatics-led discovery of osteoarthritis biomarkers and inflammatory infiltrates. Frontiers in Immunology, 13, 871008.
| Volume | 02 |
| Issue | 01 |
| Received | January 23, 2024 |
| Accepted | February 17, 2024 |
| Published | March 15, 2024 |